Automation of C. elegans lifespan measurement

Felker, Daniel P.; Robbins, Christine Reiser; McCormick, Mark

doi:10.1016/j.tma.2019.12.001

Cited by 14 publications

(9 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…), acquired strain-specific background mutations, epigenetic traits, and/or experimenter-related bias. The possibility of variance in N2 lifespan arising due to experimental-related scoring bias may be diminished in the near future by the use of auto- mated lifespan scoring techniques ( Felker et al, 2020 ; Le et al, 2020 ; Puchalt et al, 2020 ). Finally, we also have to consider that naturally occurring developmental variation may contribute to our observations.…”

Section: Discussionmentioning

confidence: 99%

Explaining inter-lab variance in C. elegans N2 lifespan: Making a case for standardized reporting to enhance reproducibility

Urban

Cavataio

Berry

et al. 2021

Experimental Gerontology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Explaining inter-lab variance in C. elegans N2 lifespan: Making a case for standardized reporting to enhance reproducibility

Urban

Cavataio

Berry

et al. 2021

Experimental Gerontology

View full text Add to dashboard Cite

“…Automation covers many areas of the process including worm handling, worm observation and downstream data analysis. Several groups have invented automated methods to quantify aging in C. elegans ( Stroustrup et al, 2013 , Xian et al, 2013 , Li et al, 2015 , Churgin et al, 2017 , Letizia et al, 2018 , Saberi-Bosari et al, 2018 , Benedetto et al, 2019 , Rahman et al, 2020 , Le et al, 2020 , reviewed in Felker et al (2020) , Puchalt et al (2021) . These include The Lifespan Machine, which monitors lifespan of C. elegans on Petri dishes in an adapted commercial flat-bed scanner.…”

Section: Reproducibility and Standardisation Of Data—an Industrial Ap...mentioning

confidence: 99%

Applying C. elegans to the Industrial Drug Discovery Process to Slow Aging

Weinkove

Zavagno

2021

Front. Aging

View full text Add to dashboard Cite

The increase in our molecular understanding of the biology of aging, coupled with a recent surge in investment, has led to the formation of several companies developing pharmaceuticals to slow aging. Research using the tiny nematode worm Caenorhabditis elegans was the first to show that mutations in single genes can extend lifespan, and subsequent research has shown that this model organism is uniquely suited to testing interventions to slow aging. Yet, with a few notable exceptions, C. elegans is not in the standard toolkit of longevity companies. Here we discuss the paths to overcome the barriers to using C. elegans in industrial drug discovery. We address the predictive power of C. elegans for human aging, how C. elegans research can be applied to specific challenges in the typical drug discovery pipeline, and how standardised and quantitative assays will help C. elegans fulfil its potential in the biotech and pharmaceutical industry. We argue that correct application of this model and its knowledge base will significantly accelerate progress to slow human aging.

show abstract

“…Common developmental and aging studies have applied correlative association of imaging and behavior or circuit activity analysis, involving different sets of animals for each respective assay. [12][13][14] Despite groups of C. elegans being isogenic, the ability to perform behavior and microscopy within the same set of animals will improve our ability to correlate cellular function and behavior, distinguishing between individual variation in response to environmental manipulation and experimental variations. Currently, an immobilization technique that can facilitate this multiplex study design is lacking.…”

Section: Introductionmentioning

confidence: 99%